Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events

Subsequent Events
9 Months Ended
Sep. 30, 2015
Subsequent Events [Abstract]  
Subsequent Events




In October 2015, the Company achieved a milestone under the CFFT award when the first patient was dosed in the Resunab clinical trial for the treatment of cystic fibrosis.  The Company informed CFFT and will receive an additional $1,250,000 for achieving the milestone (See Notes 7 and 13). Upon achievement of additional milestones set forth in the Award agreement, the Company has the potential to receive an additional $2,500,000 in future payments under the development award.